{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:25:16Z","timestamp":1792617916763,"version":"4.5.0"},"reference-count":30,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T00:00:00Z","timestamp":1473206400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Transfusion"],"published-print":{"date-parts":[[2016,11]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>The aim of this study was to evaluate the effectiveness of ferric carboxymaltose (FCM) in patients with iron deficiency anemia (IDA) secondary to gastrointestinal chronic blood loss (CBL), who received chronic transfusion support.<\/jats:p><\/jats:sec><jats:sec><jats:title>STUDY DESIGN AND METHODS<\/jats:title><jats:p>We retrospectively evaluated 38 patients with IDA (hemoglobin [Hb]\u2009&lt;\u200910 g\/dL and ferritin\u2009&lt;\u200912 ng\/mL or transferrin saturation [TSAT]\u2009&lt;\u200916%) refractory or intolerant to oral iron therapy that necessitated transfusion support in the previous 12 months. They were treated with FCM (500\u20102500 mg). The primary endpoint was to evaluate the reduction of transfusion requirements (red blood cell [RBC] units) after FCM treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The median age of the cohort was 78 years, with a male:female ratio of 22:16. Before FCM treatment a median of 6 RBC units had been transfused. At the treatment (T0) the median value of Hb was 8.7 g\/dL, the TSAT 6%, and ferritin 12 ng\/mL. The median FCM dose was 1000 mg. At 5 weeks from T0 the median Hb level was 11 g\/dL, with a median increase of 2.4 g\/dL. With a median follow\u2010up of 326 days, the median transfusion requirement was 0 RBC units, significantly lower than before T0 (p\u2009&lt;\u20090.001). Overall 17 patients still necessitated transfusion support. Twenty\u2010three patients needed retreatment with FCM for recurrence of IDA: 10 of them obtained a response again. The percentage of transfusion\u2010independent patients at median follow\u2010up was equal to 52%.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>In patients with IDA secondary to CBL, FCM significantly reduces the need of transfusions and achieves transfusion independence in half of the cases.<\/jats:p><\/jats:sec>","DOI":"10.1111\/trf.13794","type":"journal-article","created":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T15:20:48Z","timestamp":1473261648000},"page":"2720-2726","source":"Crossref","is-referenced-by-count":12,"title":["Ferric carboxymaltose reduces the number of red blood cell units transfused and allows transfusion independence to be obtained in patients with iron deficiency anemia secondary to gastrointestinal chronic blood loss"],"prefix":"10.1111","volume":"56","author":[{"given":"Ugo","family":"Salvadori","sequence":"first","affiliation":[{"name":"Immunohaematology and Transfusion Service Bozen\/Bolzano Hospital Bozen\/Bolzano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Sandri","sequence":"additional","affiliation":[{"name":"Centre for Biomedicine European Academy Bozen\/Bolzano (EURAC) Bozen\/Bolzano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Melli","sequence":"additional","affiliation":[{"name":"Transfusion Medicine Department Udine University Hospital Udine Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Polese","sequence":"additional","affiliation":[{"name":"Immunohaematology and Transfusion Service Mestre Hospital Mestre, Venezia Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Simeoni","sequence":"additional","affiliation":[{"name":"Transfusion Service San Don\u00e0 di Piave Hospital San Don\u00e0 di Piave Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Capelli","sequence":"additional","affiliation":[{"name":"Transfusion Service Belluno Hospital Belluno Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmad","family":"Al\u2010Khaffaf","sequence":"additional","affiliation":[{"name":"Immunohaematology and Transfusion Service Bozen\/Bolzano Hospital Bozen\/Bolzano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,9,7]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1017\/S1368980008002401"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-06-508325"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2318-8-1"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199312023292303"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2010.228874"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.111492"},{"key":"e_1_2_8_8_1","unstructured":"New recommendations to manage risk of allergic reactions with intravenous iron\u2010containing medicines [Internet]. London: European Medicines Agency;2013[cited 2016 Mar 30]. Available from:http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/news_and_events\/news\/2013\/06\/news_detail_001833.jsp&mid=WC0b01ac058004d5c1."},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfg579"},{"key":"e_1_2_8_10_1","first-page":"9","article-title":"Use of intravenous iron supplementation in chronic kidney disease: an update","volume":"7","author":"Macdougall IC","year":"2013","journal-title":"Iran J Kidney Dis"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200969060-00007"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/31.2.87"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2006.01084.x"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.2007.01010.x"},{"key":"e_1_2_8_15_1","unstructured":"Determina n. 867 8 ottobre 2013. Riclassificazione del medicinale per uso umano \u00abFerinject\u00bb ai sensi dell'articolo 8 comma 10 della legge 24 dicembre1993 n. 537. GU n.244 del 17\u201010\u20102013 [Internet]. Rome: Gazzetta Ufficiale della Republica Italiana; 2003 [cited 2016 Mar 30]. Available from;http:\/\/www.gazzettaufficiale.it\/eli\/id\/2013\/10\/17\/13A08349\/sg."},{"key":"e_1_2_8_16_1","unstructured":"Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity [Internet]. WHO\/NMH\/NHD\/MNM\/11.1. Geneva: World Health Organization; 2011 [cited 2016 Mar 30]. Available from:http:\/\/www.who.int\/vmnis\/indicators\/haemoglobin.pdf."},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2011.06.005"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-015-2461-x"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003643-201106001-00042"},{"key":"e_1_2_8_20_1","first-page":"1","article-title":"A fast\u2010track anaemia clinic in the Emergency Department: feasibility and efficacy of intravenous iron administration for treating sub\u2010acute iron deficiency anaemia","volume":"19","author":"Quintana\u2010D\u00edaz M","year":"2015","journal-title":"Blood Transfus"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756283X15616577"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/trf.12289"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/169107"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.121004"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2369-14-167"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/468675"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2011.03532.x"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.2147\/TCRM.S17536"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0045604"},{"key":"e_1_2_8_30_1","first-page":"157","article-title":"Cost of red blood cell transfusion: an activity\u2010based cost description","volume":"2","author":"Santini V","year":"2013","journal-title":"DCTH"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1537-2995.2012.03701.x"}],"container-title":["Transfusion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Ftrf.13794","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/trf.13794","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T13:55:01Z","timestamp":1695563701000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/trf.13794"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,7]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2016,11]]}},"alternative-id":["10.1111\/trf.13794"],"URL":"https:\/\/doi.org\/10.1111\/trf.13794","archive":["Portico"],"relation":{},"ISSN":["0041-1132","1537-2995"],"issn-type":[{"value":"0041-1132","type":"print"},{"value":"1537-2995","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,7]]}}}